|  |  |  |  |
| --- | --- | --- | --- |
| Sup. Table 1 | **COVID-19 confirmed diagnosis** | **COVID-19 ruled out** |  |
|  | Total | Moderate | Severe\* | Negative | *P* value\*\* |
| **Population characteristics**  |  |  |  |  |  |
| Number of cases  | **32** | 15 | 17 | **21** | *0.21* |
| M/F | **20/12** | 11/4 | 9/8 | **11/10** | *0.56* |
| Age (median, (IQR)) | **61 (51 - 81.5)** | 62 (52 - 78.5) | 61 (47.5 - 81.5) | **65 (47 - 72)** | *0.63* |
| Age >= 65  | **15** | 8 | 7 | **12** | *0.34* |
| Length of stay (days, median (IQR)) | **9 (7 - 21.5)** | 8 (7 - 11) | 9 (7.5 - 28) | **39 (13 - 57)** | *0.04* |
|  |  |  |  |  |  |
| **Biologic tests; median (IQR)** |  |  |  |  |  |
| Hemoglobin (g/L) | **13.2 (11.5 - 15.1)** | 14 (11.5 -15.8) | 13 (11.65 - 14.8) | **12.4 (10.7 -13.7)** | *0.16* |
| Platelet (103/mm3) | **206 (136.7 - 273)** | 173 (131.5 - 272) | 190 (144 - 274) | **218 (146.5 - 337)** | *0.75* |
| Lymphocytes (/mm3) | **975 (693.7 - 1132)** | 991 (750 - 1191) | 745 (592 - 1056.5) | **882 (665 - 1431)** | *0.22* |
| CD4 (/mm3) | **413.5 (307.2 - 544.5)** | 460 (308.5 - 579.5) | 375 (292 - 454.5) | **466 (237.5 - 793.5)** | *0.14* |
| CD4 (%)  | **43.27 (35.8 - 50.7)** | 44.8 (41.3 - 51.2) | 40.94 (32.5- 46.5) | **43.3 (34.1 - 57.7)** | *0.44* |
| CD8 T cells (/mm3) | **195 (138 - 271.5)** | 185 (140 - 274.5) | 200 (144 - 269) | **180 (99 - 325.5)** | *0.75* |
| CD8 T cells (%) | **23.74 (18.0 - 28.7)** | 20.9 (16.2 - 25) | 25.1 (20.4 - 33.9) | **20.59 (13.2 - 28.7)** | *0.30* |
| CD4/CD8 ratio | **1.88 (1.2 - 3.0)** | 2.2 (1.5 - 3.5) | 1.56 (1.2 - 2.3) | **1.92 (1.18 - 3.7)** | *0.79* |
| Neutrophils (103/mm3) | **4.36 (2.2 - 9.8)** | 2.9 (2.08 - 11.3) | 4.01 (2.2 - 7,6) | **5.46 (4.2 - 15.9)** | *0.01* |
| CRP (mg/L) | **92.25 (23.0 - 140.4)** | 49.9 (14.2 -139.8) | 103.15 (79.9 - 201.9) | **50.1 (12.3 - 130.3)** | *0.79* |
| Procalcitonin (µg/L) | **0.12 (0.08 - 0.88)** | 0.1 (0.1-0.9) | 0.4 (0.25-1) | **0.85 (0.3 - 4.8)** | *0.04* |
| Troponin (ng/L) | **16.7 (7.4 - 47.2)** | 29.65 (14.3 - 63.6) | 10.4 (7.8 - 20.4) | **43.9 (18.4 - 73.4)** | *0.01* |
|  |  |  |  |  |  |
| **Signs and symptoms at admission** |  |  |  |  |  |
| Fever | **23 (71.88 %)** | 10 (66,7 %) | 13 (76.5 %) | **9 (42.8 %)** | *0.03* |
| Headache | **6 (18.75 %)** | 2 (13.33 %) | 4 (23.5 %) | **2 (9.5 %)** | *0.36* |
| Cough | **18 (56.25 %)** | 9 (60 %) | 9 (52.9 %) | **5 (23.8 %)** | *0.02* |
| Shortness of breath / dyspnea | **13 (40.62 %)** |  4 (26,6 %) | 9 (52.9 %) | **9 (42.8 %)** | *0.87* |
| Rhinorrhoea | **2 (6.25 %)** | 2 (13.3 %) | 0 (0 %) | **1 (4.8 %)** | *0.81* |
| Taste loose /ageusia | **2 (6.25 %)** | 2 (13.3 %) | 0 (0 %) | **0 (0 %)** | *0.24* |
| Falls or falls sensations | **4 (12,5 %)** | 2 (13.3 %) | 2 (11.7%) | **0 (0 %)** | *0.09* |
| Muscle ache | **6 (18.75 %)** | 3 (20 %) | 3 (17.6 %) | **0 (0 %)** | *0.03* |
| Anorexia | **1 (3.12 %)** | 1 (6.7 %) | 0 (0 %) | **1 (4.8 %)** | *0.76* |
| Diarrhoea | **4 (12,5 %)** | 1 (6.7 %) | 3 (17.6%) | **2 (9.5 %)** | *0.74* |
| Nausea and vomiting | **6 (18.75 %)** | 1 (6.7 %) | 5 (29.4%) | **1 (4.7 %)** | *0.14* |
|  |  |  |  |  |  |
| **Chronic medical illness** |  |  |  |  |  |
| Kidney disease  | **8 (25 %)** | 4 (12.5 %) | 4 (23.5 %) | **3 (14.3 %)** | *0.35* |
| Cardiovascular diseases | **22 (68. 8 %)** | 12 (37.5%) | 10 (58.8 %) | **7 (33.3 %)** | *0.01* |
| Respiratory system disease | **6 (18.8 %)** | 2 (6.2 %) | 4 (23.5 %) | **4 (19.1 %)** | *0.98* |
| Endocrine system disease\*\*\* | **8 (25 %)** | 4 (12.5 %) | 4 (23.5 %) | **6 (28.6 %)** | *0.77* |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

\* Severe COVID-19 was defined as occurring in patient who either died or was admitted in intensive care unit at last one day.

\*\*COVID-19 confirmed group versus ruled-out group

\*\*\*Four COVID-19 confirmed patients and six COVID-19 ruled-out patients were diabetics.